Clinical InvestigationPotential Costs of Inappropriate Use of Proton Pump Inhibitors
Section snippets
MATERIALS AND METHODS
A retrospective medical record review of all patients admitted to a teaching internal medicine service at a tertiary-care urban hospital between January 1 and March 31, 2010, was performed. Patients of either gender, with an age range of 20 to 99 years, who received 40 mg of oral esomeprazole once a day within 24 hours of admission, were selected for the study if they were deemed to have a low risk for gastrointestinal (GI) bleeding. For the purpose of the study, “low risk” for GI bleeding was
RESULTS
A total of 2,094 patients were admitted to this institution during the study period. Of these, 629 (30%) patients were started on PPI within 24 hours of admission. Two hundred twenty patients were excluded from the study as follows: 168 had GI-related admitting diagnoses including 91 with upper GI hemorrhage, 39 with lower GI hemorrhage, 9 with peptic ulcer disease and 29 with abdominal pain of uncertain causative factors. Another 52 patients were excluded because they required intensive care
DISCUSSION
In the current study, 75.9% patients receiving PPI de novo lacked an FDA-approved indication for their use; and 40% of these were continued on the drug at the time of discharge. The most common inappropriate indication in these patients was GI prophylaxis, although the medical record did not reveal an appropriate reason for such indication. The rate of inappropriate use of PPI in our study is similar to the one reported previously by other authors in other regions of the country and in Europe.
CONCLUSIONS
PPIs are overused in the majority of hospitalized patients with low risk for GI bleeding, and this practice gets perpetuated at discharge. In this study, older age was a significant predictor of continuation of PPI at discharge. The cost of this phenomenon is alarming and poses a significant burden to a healthcare system struggling to reduce its costs. Physicians should keep in mind the potential side effects and the possible increased 1-year mortality risk of these drugs to use them in a
REFERENCES (35)
- et al.
Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis
Lancet
(1987) - et al.
Overuse of acid-suppressive therapy in hospitalized patients
Am J Gastroenterol
(2000) - et al.
Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly
Eur J Intern Med
(2011) - et al.
Patterns of proton pump inhibitor use in clinical practice
Am J Med
(2001) - et al.
Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis
Aliment Pharmacol Ther
(1997) - et al.
Omeprazole is more effective than cimetidine in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis
Aliment Pharmacol Ther
(1998) - et al.
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome
JAMA
(2009) - et al.
Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease
JAMA
(2005) - et al.
Proton pump inhibitor-induced acute interstitial nephritis
Br J Clin Pharmacol
(2007) - et al.
Long-term proton pump inhibitor therapy and risk of hip fracture
JAMA
(2006)
Acid-suppressive medication use and the risk for hospital-acquired pneumonia
JAMA
Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals
JAMA Intern Med
Proton pump inhibitors BPCA drug use review and duration of use analysis
Drugs to treat heartburn and stomach acid reflux: the proton pump inhibitors comparing effectiveness, safety, and price. N.p
Aciphex Prescribing Information
Nexium Prescribing Information
Prevacid Prescribing Information
Cited by (0)
The authors have no financial or other conflicts of interest to disclose.